Looking Ahead: Unmet Needs and Future Directions in the Treatment of Advanced EGFR-Mutant NSCLC

Future Perspectives and Unmet Needs

Main Discussion Topics:

• Remaining gaps in knowledge and unmet needs in EGFR-mutant non–small cell lung cancer (NSCLC)
• Novel therapies and treatment strategies on the horizon
• Challenges in treatment beyond first-line settings

Key Points for Physicians:

• Continued need for education and personalized care approaches
• Mechanisms of resistance to combination therapies remain an important area of investigation
• Management of refractory CNS metastatic disease remains challenging

Notable Insights:

Emerging therapeutic approaches of interest include antibody-drug conjugates, protein degraders (proteolysis-targeting chimeras), radioconjugates, and strategies to enhance immunotherapy responses.

Clinical Significance:

Although significant advances have been made in first-line therapy for EGFR-mutant NSCLC, ongoing research is needed to address resistance mechanisms and improve outcomes in subsequent treatment lines.